Sunday, August 28, 2016

Cipher readies regulatory filings for acne product

Cipher readies regulatory filings for acne product

October 26, 2011 by · Leave a Comment 

Tweet Cipher Pharmaceuticals (TSX:DND) is on track to file Health Canada and FDA submissions this quarter for its high-potential acne product, CIP-Isotretinoin, which is expected to trigger a $1 million milestone payment from its U.S. partner. The FDA review under PDUFA is expected to be six months. “With Lipofen generating steady revenue and our tramadol […]

Cipher signs up Canadian distributor for Tramadol

Cipher signs up Canadian distributor for Tramadol

September 26, 2011 by · Leave a Comment 

Tweet Cipher Pharmaceuticals (TSX:DND) has entered into a distribution and supply agreement with Medical Futures, a closely held Canadian pharmaceutical company, for the marketing of Durela in Canada. Durela is Cipher’s once-daily capsule formulation of tramadol, which has both immediate-release and extended-release components for the treatment of moderate-to-moderately severe chronic pain in adults. “This agreement, […]

Email Newsletters with Constant Contact
Google+